SGMT250117C12500
- 0.05
- 0.000.00%
Sagimet Biosciences Newsroom
Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)
Sagimet Biosciences Price Target Announced at $30.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30
JMP Securities Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $31
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
Sagimet Biosciences Analyst Ratings
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating
UBS Initiates Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $12
Sagimet Biosciences Initiated With a Buy at UBS
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
Sagimet Biosciences Analyst Ratings
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32
Leerink Partners Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
Sagimet Biosciences' Denifanstat Receives Buy Rating on FDA's BTD and Promising Trial Results
Sagimet Biosciences Analyst Ratings
Buy Rating for Sagimet Biosciences on Strong Phase 2b Results and Favorable Valuation Model
Buy Rating Justified: Sagimet Biosciences' Denifanstat Poised to Transform NASH Treatment Landscape